Jazz Pharmaceuticals Sets May 5 Q1 Report, Showcases ASCO Data for Ziihera and Zepzelca
Jazz Pharmaceuticals will report Q1 2026 results on May 5 and host a 4:30 p.m. ET webcast to review performance. The company will present three rapid oral and seven poster abstracts at ASCO 2026, featuring Phase 3 HERIZON-GEA-01 findings for Ziihera and Q-TWiST IMforte results for Zepzelca.
1. First Quarter 2026 Results Announcement
Jazz Pharmaceuticals will report its first quarter 2026 financial results on Tuesday, May 5, after market close, and host a webcast at 4:30 p.m. ET to review operating performance and strategic milestones. Participants can register via the company’s investor portal and access a replay following the live event.
2. ASCO 2026 Data Presentations
At the ASCO Annual Meeting in Chicago from May 29 to June 2, Jazz and its collaborators will deliver three rapid oral presentations and seven posters. Key abstracts include Phase 3 HERIZON-GEA-01 analyses of progression-free and overall survival across PD-L1 subgroups for Ziihera in HER2-positive gastroesophageal adenocarcinoma and Q-TWiST maintenance outcomes from the IMforte study of Zepzelca plus atezolizumab in extensive-stage small cell lung cancer.